(AVNS) Avanos Medical - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 643m USD | Total Return: 14.1% in 12m

Feeding Tubes, Pain Pumps, Therapy Systems, Ablation Products
Total Rating 30
Safety 30
Buy Signal 0.17
Medical Devices
Industry Rotation: -2.9
Market Cap: 643M
Avg Turnover: 5.85M USD
ATR: 3.26%
Peers RS (IBD): 81.3
Risk 5d forecast
Volatility35.9%
Rel. Tail Risk-4.58%
Reward TTM
Sharpe Ratio0.28
Alpha-12.59
Character TTM
Beta0.667
Beta Downside1.770
Drawdowns 3y
Max DD68.08%
CAGR/Max DD-0.32
EPS (Earnings per Share) EPS (Earnings per Share) of AVNS over the last years for every Quarter: "2021-03": 0.23, "2021-06": 0.21, "2021-09": 0.25, "2021-12": 0.46, "2022-03": 0.26, "2022-06": 0.41, "2022-09": 0.38, "2022-12": 0.6, "2023-03": 0.27, "2023-06": 0.37, "2023-09": 0.42, "2023-12": 0.32, "2024-03": 0.19, "2024-06": 0.29, "2024-09": 0.36, "2024-12": 0.43, "2025-03": 0.1413, "2025-06": 0.17, "2025-09": 0.22, "2025-12": 0.29, "2026-03": 0,
EPS CAGR: -50.94%
EPS Trend: -68.2%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of AVNS over the last years for every Quarter: 2021-03: 180.7, 2021-06: 186.4, 2021-09: 184.1, 2021-12: 193.4, 2022-03: 197.4, 2022-06: 170.9, 2022-09: 172.3, 2022-12: 181.6, 2023-03: 159.3, 2023-06: 169.4, 2023-09: 171.3, 2023-12: 173.3, 2024-03: 166.1, 2024-06: 171.7, 2024-09: 170.4, 2024-12: 179.6, 2025-03: 167.5, 2025-06: 175, 2025-09: 177.8, 2025-12: 180.9, 2026-03: null,
Rev. CAGR: -2.30%
Rev. Trend: -7.2%
Last SUE: 1.12
Qual. Beats: 3

Warnings

Interest Coverage Ratio -7.5 is critical

Altman Z'' -4.44 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: AVNS Avanos Medical

Avanos Medical, Inc. (AVNS) is a medical technology company. It operates globally, providing medical device solutions across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

The companys product portfolio includes digestive health products, such as enteral feeding tubes and patient feeding solutions. It also offers non-opioid pain solutions, including surgical pain pumps and cold/compression therapy systems. Additionally, Avanos provides interventional pain solutions, focusing on minimally invasive therapies like radiofrequency ablation products for chronic pain management. The medical technology sector is characterized by continuous innovation in device development.

Avanos distributes its products directly to hospitals, healthcare facilities, and other end-users. It also utilizes third-party wholesale distributors. This dual distribution model is common in the healthcare supplies industry, balancing direct sales relationships with broader market reach. Investors should consider further research to understand the companys competitive landscape and financial performance. The company was founded in 2014 and is headquartered in Alpharetta, Georgia.

Headlines to Watch Out For
  • Enteral feeding product sales drive revenue growth
  • Surgical pain pump adoption impacts profitability
  • COOLIEF chronic pain product market penetration
  • Healthcare provider purchasing decisions influence sales
  • Regulatory approvals for new medical devices
Piotroski VR‑10 (Strict) 4.5
Net Income: -67.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.17 > 1.0
NWC/Revenue: 27.12% < 20% (prev 33.08%; Δ -5.95% < -1%)
CFO/TA 0.07 > 3% & CFO 74.7m > Net Income -67.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.15 > 1.5 & < 3
Outstanding Shares: last quarter (46.4m) vs 12m ago 0.87% < -2%
Gross Margin: 49.77% > 18% (prev 0.56%; Δ 4.92k% > 0.5%)
Asset Turnover: 62.95% > 50% (prev 59.59%; Δ 3.36% > 0%)
Interest Coverage Ratio: -7.49 > 6 (EBITDA TTM -19.5m / Interest Expense TTM 7.80m)
Altman Z'' -4.44
A: 0.18 (Total Current Assets 355.4m - Total Current Liabilities 165.2m) / Total Assets 1.07b
B: -0.73 (Retained Earnings -779.9m / Total Assets 1.07b)
C: -0.05 (EBIT TTM -58.4m / Avg Total Assets 1.11b)
D: -2.75 (Book Value of Equity -811.4m / Total Liabilities 295.5m)
Altman-Z'' Score: -4.44 = D
Beneish M -3.23
DSRI: 0.77 (Receivables 103.8m/132.8m, Revenue 701.2m/687.8m)
GMI: 1.12 (GM 49.77% / 55.63%)
AQI: 1.01 (AQ_t 0.54 / AQ_t-1 0.53)
SGI: 1.02 (Revenue 701.2m / 687.8m)
TATA: -0.13 (NI -67.9m - CFO 74.7m) / TA 1.07b)
Beneish M-Score: -3.23 (Cap -4..+1) = AA
What is the price of AVNS shares? As of April 12, 2026, the stock is trading at USD 14.18 with a total of 215,187 shares traded.
Over the past week, the price has changed by +2.53%, over one month by +8.16%, over three months by +18.46% and over the past year by +14.08%.
Is AVNS a buy, sell or hold? Avanos Medical has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold AVNS.
  • StrongBuy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AVNS price?
Analysts Target Price 14 -1.3%
Avanos Medical (AVNS) - Fundamental Data Overview as of 08 April 2026
P/E Forward = 30.6748
P/S = 0.9173
P/B = 0.8337
Revenue TTM = 701.2m USD
EBIT TTM = -58.4m USD
EBITDA TTM = -19.5m USD
Long Term Debt = 90.3m USD (from longTermDebt, last quarter)
Short Term Debt = 18.4m USD (from shortTermDebt, last quarter)
Debt = 129.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.3m USD (from netDebt column, last quarter)
Enterprise Value = 682.5m USD (643.2m + Debt 129.1m - CCE 89.8m)
Interest Coverage Ratio = -7.49 (Ebit TTM -58.4m / Interest Expense TTM 7.80m)
EV/FCF = 15.84x (Enterprise Value 682.5m / FCF TTM 43.1m)
FCF Yield = 6.31% (FCF TTM 43.1m / Enterprise Value 682.5m)
FCF Margin = 6.15% (FCF TTM 43.1m / Revenue TTM 701.2m)
Net Margin = -9.68% (Net Income TTM -67.9m / Revenue TTM 701.2m)
Gross Margin = 49.77% ((Revenue TTM 701.2m - Cost of Revenue TTM 352.2m) / Revenue TTM)
Gross Margin QoQ = 47.54% (prev 45.61%)
Tobins Q-Ratio = 0.64 (Enterprise Value 682.5m / Total Assets 1.07b)
Interest Expense / Debt = 1.47% (Interest Expense 1.90m / Debt 129.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -46.1m (EBIT -58.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.15 (Total Current Assets 355.4m / Total Current Liabilities 165.2m)
Debt / Equity = 0.17 (Debt 129.1m / totalStockholderEquity, last quarter 778.2m)
 Debt / EBITDA = -2.02 (negative EBITDA) (Net Debt 39.3m / EBITDA -19.5m)
 Debt / FCF = 0.91 (Net Debt 39.3m / FCF TTM 43.1m)
Total Stockholder Equity = 793.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.10% (Net Income -67.9m / Total Assets 1.07b)
RoE = -8.56% (Net Income TTM -67.9m / Total Stockholder Equity 793.0m)
RoCE = -6.61% (EBIT -58.4m / Capital Employed (Equity 793.0m + L.T.Debt 90.3m))
 RoIC = -5.14% (negative operating profit) (NOPAT -46.1m / Invested Capital 896.9m)
 WACC = 7.13% (E(643.2m)/V(772.3m) * Re(8.33%) + D(129.1m)/V(772.3m) * Rd(1.47%) * (1-Tc(0.21)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF] Terminal Value 81.21% ; FCFF base≈59.0m ; Y1≈56.5m ; Y5≈55.0m
[DCF] Fair Price = 24.88 (EV 1.20b - Net Debt 39.3m = Equity 1.16b / Shares 46.5m; r=7.13% [WACC]; 5y FCF grow -5.62% → 3.0% )
EPS Correlation: -68.18 | EPS CAGR: -50.94% | SUE: -4.0 | # QB: 0
Revenue Correlation: -7.25 | Revenue CAGR: -2.30% | SUE: 1.12 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.16 | Chg7d=-0.060 | Chg30d=-0.080 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.00 | Chg7d=+0.000 | Chg30d=+0.050 | Revisions Net=+1 | Growth EPS=+6.4% | Growth Revenue=+1.2%
EPS next Year (2027-12-31): EPS=1.25 | Chg7d=+0.000 | Chg30d=+1.250 | Revisions Net=-1 | Growth EPS=+25.0% | Growth Revenue=+4.2%
External Resources
Dataroma Stockcircle